Holen Sie sich die Stockscreener-App
19.67
1.13%
0.22
Schlusskurs vom Vortag:
$19.45
Offen:
$19.67
24-Stunden-Volumen:
2.72M
Relative Volume:
0.87
Marktkapitalisierung:
$62.84B
Einnahmen:
$29.91B
Nettoeinkommen (Verlust:
$1.30B
KGV:
48.50
EPS:
0.4056
Netto-Cashflow:
$3.49B
1W Leistung:
+5.02%
1M Leistung:
+5.53%
6M Leistung:
+10.63%
1J Leistung:
+41.71%
1-Tages-Spanne:
$19.56
$19.70
1-Wochen-Bereich:
$18.52
$19.89
52-Wochen-Spanne:
$12.99
$19.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment - GlobeNewswire Inc.
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Takeda stock advances after U.S. FDA clears MIMRYLO cancer drug - AD HOC NEWS
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - valueresearchonline.com
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneBlock Trade Flow - vinanet.vn
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelBPI Bull Correction - vinanet.vn
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Nigeria
6 High-Yield International Dividend Stocks Analysts Love - Forbes
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Takeda Pharmaceutical Co Adr-Aktie (TAK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lauren Rusckowski Duprey | Chief Transformation Officer |
Sep 10 '26 |
Proposed Sale |
18.37 |
34,535 |
634,408 |
0 |
| Plump Andrew Stewart | President, R&D |
Sep 02 '26 |
Sale |
18.49 |
116,191 |
2,148,372 |
145,465 |
| Plump Andrew Stewart | Officer |
Sep 02 '26 |
Proposed Sale |
18.49 |
116,191 |
2,148,372 |
0 |
| Plump Andrew Stewart | President, R&D |
Aug 19 '26 |
Sale |
18.49 |
19,651 |
363,347 |
261,656 |
| Plump Andrew Stewart | Officer |
Aug 19 '26 |
Proposed Sale |
18.49 |
19,651 |
363,348 |
0 |
| Greenway Nicola Deidre Petal | Chief Human Resources Officer |
Aug 18 '26 |
Sale |
18.11 |
12,980 |
235,118 |
40,049 |
| Nicola Greenway | Chief Human Resources Officer |
Aug 14 '26 |
Proposed Sale |
17.39 |
12,980 |
225,722 |
0 |
| Shannon Elaine Mary | Pres., Global Supply & Quality |
Aug 11 '26 |
Sale |
17.55 |
20,363 |
357,371 |
67,311 |
| Elaine Shannon | President, Global Supply & Qua |
Aug 11 '26 |
Proposed Sale |
17.45 |
20,363 |
355,334 |
0 |
| Pacheco Rhonda Janice | President, U.S. Business Unit |
Aug 10 '26 |
Sale |
17.10 |
16,901 |
289,007 |
182,507 |
0.95%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):